Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 13/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216213 | 1.00 | SMYD3 (0.39) | SMYD3DPP4DPP7DPP8DPP9 | |
| SCHEMBL23216624 | 0.94 | DPP4 (0.38) | SMYD3DPP4DPP7DPP8DPP9 | |
| SCHEMBL23215346 | 0.88 | DPP4 (0.34) | DPP4DPP7DPP8DPP9EPHX2 | |
| SCHEMBL23216090 | 0.85 | CPN1 (0.36) | DPP4DPP7DPP8DPP9EPHX2 | |
| SCHEMBL23217452 | 0.84 | SLC6A2 (0.37) | DPP4DPP7 | |
| SCHEMBL23215684 | 0.83 | DPP4 (0.39) | DPP4DPP7DPP8DPP9MEN1 | |
| SCHEMBL23215565 | 0.83 | DPP4 (0.33) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL23215675 | 0.83 | MGLL (0.35) | DPP4DPP7DPP8MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL23216007 | 0.82 | DPP4 (0.46) | SMYD3DPP4DPP7DPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL23216211 | 0.82 | DPP4 (0.46) | SMYD3DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SMYD3 520/4885DPP4 2667/4885DPP7 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.